Physician profile
Insaf Ally
NPI 1750635801
$989.51
in general payments reported to CMS, 2019-2025
11 companies · $594 in 2025
The $594 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $144 · 2024: $251 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.51 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $401.19 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $182.11 | 2023-2025 | Vraylar |
| Amgen INC. | $117.71 | 2025 | Otezla, Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $78.00 | 2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $58.72 | 2024-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $40.85 | 2025 | Zepbound, Mounjaro |
| Verona Pharma, INC. | $26.47 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $25.84 | 2024 | Inspire |
| Sanofi Pasteur INC. | $24.84 | 2025 | |
| Gilead Sciences, INC. | $18.30 | 2024 | |
| Abbott Laboratories | $15.48 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Insaf Ally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.